<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743351</url>
  </required_header>
  <id_info>
    <org_study_id>PT-001</org_study_id>
    <nct_id>NCT02743351</nct_id>
  </id_info>
  <brief_title>Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Non-randomized/2 Randomized Study of ProTmuneâ„¢ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1 Non-randomized/Phase 2 Randomized, open-label, prospectively and
      historically controlled trial of the safety and efficacy of a single ProTmune ex vivo
      programmed mobilized peripheral blood (mPB) cells for hematopoietic cell transplantation
      (HCT) in adult subjects aged 18 to 70 years with hematologic malignancies. A maximum of 70
      total eligible subjects will be enrolled and treated in the trial at approximately 10-12
      centers in the US and EU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment related AEs as assessed by CTCAE grading scale v.4.0</measure>
    <time_frame>2 Years</time_frame>
    <description>Assessments include vital signs collection, physical examination findings, clinical laboratory assessments and electrocardiographic data through a 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients that experience Grade A-D acute Graft vs Host Disease (aGvHD)</measure>
    <time_frame>by Day 100</time_frame>
    <description>GvHD assessments of skin, liver and gastrointestinal involvement will be required to calculate the incidence of Grades A through D (CIBMTR) aGvHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients that experience CMV viremia</measure>
    <time_frame>by Day 100</time_frame>
    <description>Laboratory testing for CMV viremia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with CMV Tissue-invasive disease</measure>
    <time_frame>by Day 100</time_frame>
    <description>Laboratory testing for CMV tissue-invasive disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Febrile Neutropenia</measure>
    <time_frame>2 Years</time_frame>
    <description>Incidence of febrile neutropenia per Infectious Disease Society of America Guidelines on Febrile Neutropenia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>ProTmune</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProTmune</intervention_name>
    <description>Ex-vivo, programmed mobilized peripheral blood (mPB) cells</description>
    <arm_group_label>ProTmune</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control Arm</intervention_name>
    <description>Untreated mobilized peripheral blood (mPB) cells</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male and female patients aged 18 to 70 years, inclusive;

          2. Patients must be CMV seropositive and with no evidence of detectable CMV replication
             at baseline; 3 Patients must have a hematologic malignancy for which allogeneic
             hematopoietic peripheral blood cell transplantation is deemed clinically appropriate.

        Eligible diseases and stages include the following:

          1. Acute myeloid leukemia

          2. Acute lymphoblastic leukemia, including T lymphoblastic lymphoma with a history of
             marrow involvement

          3. Myelodysplatic Syndrome (in the Phase 2 portion of the study only) 4.Availability of
             a suitable 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated mPB donor; 5.Adequate
             performance status, defined as Karnofsky score greater than 70%; 6.For female
             patients of childbearing potential, all of the following criteria must be met:

               -  They are not pregnant (i.e., female patients must have a negative serum
                  pregnancy test at screening);

               -  They are not breastfeeding;

               -  They do not plan to become pregnant during the study; and

               -  They are using an effective method of contraception from screening to the end of
                  the study, unless their sexual partner is surgically sterile 7.For male
                  patients, agreement to use condoms with spermicide during sexual intercourse
                  from screening to the end of study; and 8.Willingness and ability to sign an
                  IRB/IEC approved ICF before performance of any study specific procedures or
                  tests and to comply with protocol visits, and study procedures.

        Key Exclusion Criteria:

          1. Positive serology for human immunodeficiency virus (HIV) or human T-cell lymphotropic
             virus (HTLV) at any time prior to enrollment;

          2. Currently active bacterial, viral, or fungal infection (progression of clinical
             symptoms despite therapy);

          3. Prior autologous or allogeneic HCT;

          4. Secondary or treatment-related hematologic malignancies;

          5. Active malignancy, other than the one for which the allogeneic mPB transplant is
             being performed, within 12 months of enrollment, excluding superficial basal cell and
             carcinoma in situ cervical cancer;

          6. Pulmonary disease, renal dysfunction, hepatic disease, cardiac disease, neurologic
             disease;

          7. Participation in another clinical trial involving an investigational product within
             30 days prior to screening; or

          8. Any condition or therapy, which, in the opinion of the Investigator, might pose a
             risk to the patient or make participation in the study not in the best interest of
             the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel S Dychter, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Golnaz Namdar</last_name>
      <phone>626-218-0061</phone>
      <email>gnamdar@coh.org</email>
    </contact>
    <investigator>
      <last_name>Chatchada Karanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplant</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie R Coleman, RN BSN</last_name>
      <phone>317-528-5500</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>John R Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Ventimiglia</last_name>
      <phone>313-576-9271</phone>
      <email>ventimim@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Abhinav Deol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Cox</last_name>
      <phone>615-524-4174</phone>
      <email>amber.cox@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Carlos Bachier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Candler</last_name>
      <phone>804-828-4732</phone>
      <email>kcandler@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>John McCarty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 9, 2016</lastchanged_date>
  <firstreceived_date>February 9, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Transplants</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <keyword>HCT</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
